Axsome Therapeutics, Inc. (AXSM) Q3 2025 Earnings Call

Investor webinar replay

Replay transcript excerpt

Good morning and welcome to the Axiom Therapeutics third quarter 2025 earnings conference call. My name is Daryl and I will be your operator for today's call. At this time, all participants are in a listen-only mode. Later, there will be a question and answer session and instructions will be given at that time. Please note that this call is being recorded. I would now like to hand the call over to Darren Oplin, Senior Director of Corporate Communications. Please go ahead. Thank you, Daryl. Good morning, everyone. Thank you for joining us for ACTSOM's Third Quarter 2025 Earnings Conference Call. With us today are Dr. Ariel Tabito, our Chief Executive Officer, Nick Pizzi, our Chief Financial Officer, and Ari Maisel, our Chief Commercial Officer, who will begin our call with prepared remarks. Marcus Jacobson, our Chief Operating Officer, and Hunter Murdoch, our General Counsel, will also be available for Q&A. This morning, to today's call. Please note that today's discussion includes forward-looking statements regarding our financial performance, commercial strategy, and operational plans, including research, development, and regulatory activities. These statements are based on current expectations and assumptions and are subject to risks and uncertainties that may cause actual results to differ materially. Please refer to our SEC filings, including our quarterly and annual reports, for a description of these and other risks. You are cautioned not to rely on these forward-looking statements, which are made only as of today, and the company disclaims any obligation to update such statements. And now, I'll turn the call over to Ariel. Thank you, Darren, and good morning, everyone. Axiom continues to lead in CNS innovation, driven by disciplined execution and a clear focus...